 Immunovant Inc NASDAQ: IMVT has aligned with the FDA Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 trials to evaluate batoclimab in thyroid eye disease TED. Immunovant expects to initiate its Phase 3 TED program in 2H of 2022 and is expected. 